199875-69-9 Usage
Description
N-Arachidonoyldopamine (NADA) is an endogenous conjugate of arachidonic acid and dopamine, which serves as an endogenous capsaicin-like substance in the central nervous system (CNS) acting at TRPV1 channels. It exhibits a distinct signaling profile from any known cannabinoid and acts as a selective cannabinoid CB1 agonist. Additionally, NADA functions as a competitive inhibitor of FAAH (Fatty Acid Amide Hydrolase) and anandamide transport, modulating acute systemic inflammation via non-hematopoietic TRPV1.
Uses
Used in Pharmaceutical Applications:
NADA is used as an endogenous CB1 agonist for its potential therapeutic effects in various conditions. Its agonistic activity at CB1 receptors may contribute to the modulation of pain, inflammation, and other physiological processes.
Used in Neurological Applications:
As a vanilloid agonist, NADA is used for its potential role in modulating TRPV1 channels, which are involved in pain sensation, temperature regulation, and other sensory functions. This application may lead to the development of novel treatments for neurological disorders and pain management.
Used in Enzyme Inhibition:
NADA is used as a competitive inhibitor of FAAH, which is responsible for the degradation of endocannabinoids. By inhibiting FAAH, NADA may help increase the levels of endocannabinoids in the body, potentially leading to therapeutic benefits in various conditions related to the endocannabinoid system.
Used in Inflammation Modulation:
NADA is used as a modulator of acute systemic inflammation via non-hematopoietic TRPV1. Its ability to modulate inflammation may contribute to the development of treatments for inflammatory diseases and conditions.
Used in Drug Delivery Systems:
NADA's properties as an endogenous CB1 agonist, vanilloid agonist, and FAAH inhibitor make it a potential candidate for incorporation into drug delivery systems. These systems could be designed to improve the bioavailability, targeting, and therapeutic outcomes of NADA in various medical applications.
Biological Activity
Potent endogenous cannabinoid and vanilloid receptor agonist, with no action at dopamine receptors. Selective for CB 1 over CB 2 receptors (K i values are 0.25 and 12 μ M respectively), and potent agonist at TRPV1 (VR1) receptors (EC 50 ~ 50 nM). Metabolically stable and competitively inhibits FAAH and anandamide transport. Has cannabinoid and vanilloid actions in vivo . Also available as part of the Endocannabinoid Tocriset? .
References
1) Huang?et al.?(2002),?An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors; Proc. Natl. Acad. Sci. USA,?99?8400
2) Bisogno?et al.?(2000),?N-acyl-dopamines: novel synthetic CB(1) cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo; Biochem. J.,?351 Pt 3?817
3) Redmund?et al.?(2016),?Identification of N-arachidonoyl dopamine as a highly biased ligand at cannabinoid CB1 receptors; Br. J. Pharmacol.,?173?115
4) Petrocellis?et al.?(2000),?Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin-like activity; FEBS Lett.,?483?52
5) Lawton?et al.?(2017),?N-Arachidonoyl Dopamine Modulates Acute Systemic Inflammation via Nonhematopoietic TRPV1; J. Immunol.,?199?1465
Check Digit Verification of cas no
The CAS Registry Mumber 199875-69-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,9,9,8,7 and 5 respectively; the second part has 2 digits, 6 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 199875-69:
(8*1)+(7*9)+(6*9)+(5*8)+(4*7)+(3*5)+(2*6)+(1*9)=229
229 % 10 = 9
So 199875-69-9 is a valid CAS Registry Number.
